Digitalis Today: From Doctrine to Disrepute to Disciplined Reconsideration

Cardiac glycosides have undergone one of the most paradoxical trajectories in cardiovascular therapeutics, evolving from foundational heart failure therapy to near abandonment in the modern era. Although the Digitalis Investigation Group (DIG) trial demonstrated substantial reductions in worsening heart failure hospitalizations, the absence of mortality benefit and subsequent toxicity concerns-particularly in women exposed to greater serum concentrations-led to therapeutic disrepute. Contemporary evidence now supports a more disciplined reassessment. Recent randomized trials, including Digitoxin to Improve Outcomes in Patients with Advanced Chronic Heart Failure (DIGIT-HF) and Digoxin Evaluation in Chronic Heart Failure: Investigational Study in Outpatients in the Netherlands (DECISION), together with a contemporary meta-analysis, demonstrate consistent directional reductions in worsening heart failure events with low-dose digitalis therapy, without excess mortality when serum concentrations are carefully controlled. These findings suggest that the historical toxicity narrative largely reflected excessive drug exposure rather than intrinsic biologic hazard. Digitalis glycosides should not be viewed as mortality-reducing "foundational" therapy but rather as complementary agents for selected patients with persistent residual risk despite optimized guideline-directed therapy, particularly those with recurrent decompensation or concomitant atrial fibrillation.